To compensate for the higher initial tumor burden, a higher dose of 5 X 106 HER2-BBz or CD19-BBz-CAR T cells were administered IV and tumor size post-treatment was measured twice weekly by bioluminescence (Fig. 5a). This evidence concerns the gene CD19 and neoplasm.